Macrogenics (MGNX) Amortizatization of Intangibles (2019 - 2026)
Macrogenics (MGNX) posted quarterly Amortizatization of Intangibles of $737000.0 for Q1 2026, up 304.95% year-over-year from $182000.0 in Q1 2025, and up 14.44% quarter-over-quarter from $644000.0 in Q4 2025.
Powered by 
Analysis
Macrogenics (MGNX) Amortizatization of Intangibles (2019 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Amortizatization of Intangibles for 8 consecutive years, with $737000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 304.95% year-over-year to $737000.0; the TTM figure through Mar 2026 stood at $2.2 million (up 31.37% YoY), while the FY2025 annual figure was $1.6 million, down 41.35% from the prior year.
- Amortizatization of Intangibles climbed to $737000.0 in Q1 2026 per MGNX's latest filing, from $644000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.9 million in Q3 2023 and bottomed at -$334000.0 in Q1 2022.
- Historically, Amortizatization of Intangibles has averaged $576235.3 across 5 years, with a median of $372000.0 in 2023.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles jumped 1771.43% — and 2024, when it tumbled 89.29%.
- Macrogenics' Amortizatization of Intangibles stood at $337000.0 in 2022, then soared by 412.76% to $1.7 million in 2023, then plunged by 89.29% to $185000.0 in 2024, then jumped by 248.11% to $644000.0 in 2025, then climbed by 14.44% to $737000.0 in 2026.
- Business Quant data shows MGNX's Amortizatization of Intangibles at $737000.0 in Q1 2026, $644000.0 in Q4 2025, and $511000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Macrogenics | 284.90 Mn | 171.00 Mn | - | 445,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 445,000.00 |
| Mar 31, 2026 | 737,000.00 |
| Dec 31, 2025 | 644,000.00 |
| Sep 30, 2025 | 511,000.00 |
| Jun 30, 2025 | 311,000.00 |
| Mar 31, 2025 | 182,000.00 |
| Dec 31, 2024 | 185,000.00 |
| Sep 30, 2024 | 371,000.00 |
| Jun 30, 2024 | 939,000.00 |
| Mar 31, 2024 | 1.32 Mn |
| Dec 31, 2023 | 1.73 Mn |
| Sep 30, 2023 | 1.87 Mn |
| Jun 30, 2023 | 1.03 Mn |
| Mar 31, 2023 | 372,000.00 |
| Dec 31, 2022 | 337,000.00 |
| Sep 30, 2022 | -112,000.00 |
| Jun 30, 2022 | -294,000.00 |
| Mar 31, 2022 | -334,000.00 |
| Dec 31, 2021 | -340,000.00 |
| Sep 30, 2021 | -459,000.00 |